Compare Gilead Sciences, Inc. (GILD) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs NetFlix Inc — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while NetFlix Inc trades at $70.3 (market cap $298.01B). The key difference: NetFlix Inc is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and NetFlix Inc for 125 Days on average.
| GILD | NFLX | |
|---|---|---|
Market Cap | $182.40B | $298.01B |
Volume | 4,469,821 | 45,805,108 |
Sector | Health | Media |
52-Week High | $155.80 | $124.13 |
52-Week Low | $117.18 | $67.06 |
Typical Hold Time | 111 Days | 125 Days |
Enterprise Value | $205.46B | $303.19B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Netflix (NFLX) trades at $71.58, up 2.7% with strong fundamentals including 49.5% ROE and consistent earnings beats. The stock faces technical headwinds with bearish moving averages despite positive sentiment from institutional buying. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 25% upside potential from current levels.
Netflix presents a compelling growth story with expanding profit margins and robust cash flow generation. Key risks include intensifying streaming competition and content cost pressures. The company's scale advantages and pricing power support premium valuation, though technical indicators suggest near-term consolidation may precede further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
